{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:25:17Z","timestamp":1774121117236,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.cllc.2011.06.004","type":"journal-article","created":{"date-parts":[[2011,7,23]],"date-time":"2011-07-23T22:29:19Z","timestamp":1311460159000},"page":"307-312","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non\u2013Small-Cell Lung Cancer With Pleural Effusion"],"prefix":"10.1016","volume":"12","author":[{"given":"Katsuhiro","family":"Masago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Togashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahide","family":"Fukudo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Terada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Irisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Sakamori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hak","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Mio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"Inui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michiaki","family":"Mishima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2011.06.004_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib2","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1200\/JCO.2002.10.112","article-title":"ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial","volume":"20","author":"Ranson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib3","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","article-title":"Erlotinib in previously treated non-small-cell lung cancer","volume":"353","author":"Shepherd","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cllc.2011.06.004_bib5","doi-asserted-by":"crossref","first-page":"6414","DOI":"10.1158\/1078-0432.CCR-05-0790","article-title":"Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen","volume":"11","author":"Johnson","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2011.06.004_bib6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1200\/JCO.2006.07.5754","article-title":"Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer","volume":"25","author":"Jackman","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib7","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1097\/JTO.0b013e318183aa1f","article-title":"Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2","volume":"3","author":"Hesketh","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1200\/JCO.2007.13.2720","article-title":"Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2","volume":"26","author":"Lilenbaum","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib9","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1200\/JCO.2007.15.2280","article-title":"Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21","volume":"26","author":"Wheatley-Price","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib10","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cpt197823168","article-title":"Effect of pleural effusion on high-dose methotrexate kinetics","volume":"23","author":"Evans","year":"1978","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cllc.2011.06.004_bib11","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00280-002-0512-9","article-title":"The effect of malignant effusions on methotrexate disposition","volume":"50","author":"Li","year":"2002","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2011.06.004_bib12","doi-asserted-by":"crossref","first-page":"3267","DOI":"10.1200\/JCO.2001.19.13.3267","article-title":"Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies","volume":"19","author":"Hidalgo","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib13","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.1200\/JCO.2004.08.189","article-title":"Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor","volume":"22","author":"Tan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib14","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1124\/dmd.105.007765","article-title":"Metabolism and excretion of erlotinib, a small molecule inhibitor of epidermal growth factor receptor tyrosine kinase, in healthy male volunteers","volume":"34","author":"Ling","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.cllc.2011.06.004_bib15","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1215\/S1522851705000451","article-title":"Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma","volume":"8","author":"Prados","year":"2006","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2011.06.004_bib17","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jchromb.2004.10.016","article-title":"Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection","volume":"814","author":"Zhang","year":"2005","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1016\/j.cllc.2011.06.004_bib18","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00280-007-0494-8","article-title":"Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors","volume":"61","author":"Yamamoto","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2011.06.004_bib19","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0091270005284193","article-title":"Evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects","volume":"46","author":"Frohna","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.cllc.2011.06.004_bib20","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1172\/JCI110130","article-title":"Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions","volume":"67","author":"Howell","year":"1981","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cllc.2011.06.004_bib21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/BF00434360","article-title":"A case report and description of the pharmacokinetic behavior of intrapleurally instilled etoposide","volume":"14","author":"Jones","year":"1985","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2011.06.004_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF02897262","article-title":"Intrapleural etoposide for malignant effusion","volume":"26","author":"Holoye","year":"1990","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cllc.2011.06.004_bib23","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/0277-5379(91)90129-2","article-title":"Regional pharmacokinetic selectivity of intrapleural cisplatin","volume":"27","author":"Bogliolo","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2011.06.004_bib24","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1200\/JCO.1992.10.6.1001","article-title":"Intrapleural cisplatin and mitomycin for malignant mesothelioma following pleurectomy: pharmacokinetic studies","volume":"10","author":"Rusch","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib25","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1023\/A:1008203100410","article-title":"Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion","volume":"8","author":"Lerza","year":"1997","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2011.06.004_bib26","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000007183","article-title":"Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer","volume":"45","author":"Tohda","year":"1999","journal-title":"Chemotherapy"},{"key":"10.1016\/j.cllc.2011.06.004_bib27","first-page":"171","article-title":"Pharmacokinetics of intrapleural cisplatin for the treatment of malignant pleural effusions","volume":"7","author":"Monjanel-Mouterde","year":"2000","journal-title":"Oncol Rep"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411001392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730411001392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:52:40Z","timestamp":1761504760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730411001392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S1525730411001392"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2011.06.004","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma and Pleural Fluid Pharmacokinetics of Erlotinib and its Active Metabolite OSI-420 in Patients With Non\u2013Small-Cell Lung Cancer With Pleural Effusion","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2011.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}